Focused On-demand Library for Probable C-mannosyltransferase DPY19L2

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

Our top-notch dedicated system is used to design specialised libraries for enzymes.

Fig. 1. The sreening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.

Key features that set our library apart include:

The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

Q6NUT2

UPID:

D19L2_HUMAN

Alternative names:

Dpy-19-like protein 2; Protein dpy-19 homolog 2

Alternative UPACC:

Q6NUT2; A4FVC1; B4E191; Q3ZCX2; Q6UWG8; Q96LZ9

Background:

The Probable C-mannosyltransferase DPY19L2, also known as Dpy-19-like protein 2 or Protein dpy-19 homolog 2, plays a crucial role in human biology. It is primarily involved in the C-mannosylation of tryptophan residues on target proteins. This enzyme is essential during spermatogenesis, facilitating sperm head elongation and acrosome formation, as well as acrosome attachment to the nuclear envelope. Its unique functions underscore its importance in reproductive biology.

Therapeutic significance:

Given its pivotal role in spermatogenesis, particularly in sperm head elongation and acrosome formation, DPY19L2 is directly linked to Spermatogenic failure 9, a disorder characterized by infertility due to spermatogenesis defects. Understanding the role of DPY19L2 could open doors to potential therapeutic strategies for treating infertility issues related to spermatogenesis defects.